2017
Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products
Sharfstein J, Miller J, Davis A, Ross J, McCarthy M, Smith B, Chaudhry A, Alexander G, Kesselheim A. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. The Journal Of Law, Medicine & Ethics 2017, 45: 7-23. DOI: 10.1177/1073110517750615.Commentaries, Editorials and LettersYale Law SchoolEffective medical productsSuch medical productsMedical productsJohn Arnold FoundationLaw schoolsCongressional authorizationDevelopment of SafeYale Medical SchoolFDA practiceCongressional actionRegulatory statusRegulatory processesTransparencyPolicy constraintsJohns Hopkins Bloomberg SchoolPractical recommendationsPublicPublic healthTask ForceSpecific recommendationsRecommendationsPracticeBlueprintAuthorization
2008
Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional survey
Ross JS, Nuñez-Smith M, Forsyth BA, Rosenbaum JR. Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional survey. BMC Public Health 2008, 8: 378. PMID: 18973674, PMCID: PMC2590615, DOI: 10.1186/1471-2458-8-378.Peer-Reviewed Original ResearchConceptsCervical cancer screeningCervical cancerCross-sectional surveyCancer screeningCervical cancer screening recommendationsEthnic differencesCancer screening recommendationsPerceptions of adherenceNon-significant tendencyScreening recommendationsUniversity HospitalEthnic disparitiesPhysiciansWomenCancerLess adherentAdherenceConvenience sampleHealth careCareScreeningBackgroundRacialAsiansRecommendationsResultsOverall